Glyxambi Side Effects And An FDA Safety Communication

A U.S. Food and Drug Administration (FDA) safety communication discusses side effects for certain diabetes drugs in the SGLT2 inhibitor and DPP-4 class, including Glyxambi. Among Glyxambi side effects noted in the communication are ketoacidosis, or dangerously high blood acid levels, severe joint pain, and urinary tract infections. Glyxambi is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination. It is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes, bad drug attorneys note.

If you or a loved one suffered complications after taking Glyxambi, contact Attorney Group today to discuss your options in a free, confidential, no-obligation consultation. We can answer your questions, and if you decide to pursue a claim for compensation, we can connect you with an affiliated Glyxambi lawsuit attorney who can assist you throughout the legal process.

Important: The time you have to pursue a claim is limited. Contact us for more information.

FDA Safety Communications Discusses Diabetes Drug Side Effects

Glyxambi is developed and marketed by Boehringer Ingelheim Pharmaceuticals in collaboration with Eli Lilly and Company. The drug was approved by the FDA in 2015 to treat type 2 diabetes. According to the safety communication released by the FDA in August 2015, DPP-4 inhibitors, including Glyxambi, may cause joint pain that can be severe and disabling, with some patients requiring hospitalization.

In May 2015, the FDA issued a safety communication cautioning that SGLT2 inhibitors, including Glyxambi, may also be linked to an increased risk of ketoacidosis, high levels of ketones (blood acids) that could require hospitalization for the patient. In the FDA’s announcement, the agency stated that from March 2013 to June 2014, it had received 20 reports of diabetic ketoacidosis, ketoacidosis or ketosis in patients treated with SGLT2 inhibitors. All 20 patients required hospitalization or visits to hospital emergency rooms for treatment. Since that time, the FDA has received additional reports concerning ketoacidosis and SGLT2 inhibitors and an updated safety information from the agency was released in December 2015 adding warnings to the labels for Glyxambi and other SGLT2 inhibitors.

The FDA indicated that users of SGLT2 inhibitor diabetes drugs, including Glyxambi, have been hospitalized or required emergency room treatment after suffering symptoms of ketoacidosis. These symptoms may include:

  • Abdominal pain
  • Nausea or vomiting
  • Confusion, Sleepiness or fatigue
  • Difficulty breathing

In addition to Glyxambi, other SGLT2 inhibitors included in the FDA warning are marketed under the following names:

  • Xigduo XR (dapagliflozin and metformin extended-release)
  • Farxiga (dapagliflozin)
  • Invokana (canagliflozin)
  • Jardiance (empagliflozin)
  • Invokamet (canagliflozin and metformin)
  • Synjardy (empagliflozin and metformin)

Glyxambi side effects may include:

  • Yeast Infection
  • Hypoglycemia
  • Pancreatitis
  • Kidney problems
  • Ketoacidosis
  • Dehydration
  • Urinary tract infection
  • Joint pain
  • Nausea
  • Dizziness

Injured Patients May Be Entitled to Compensation

Drug manufacturers have a duty to ensure their products are accompanied by full and accurate instructions and warnings to guide prescribing doctors and other health care providers in making treatment decisions. If a drug maker fails to fulfill this duty, it could be held liable in lawsuits for injuries that may result.

Patients who have been injured by Glyxambi may be entitled to compensation for damages, including:

  • Medical expenses
  • Pain, suffering, and mental anguish
  • Loss of income or ability to work

If a patient dies from complications after taking Glyxambi, his or her family members may be able to pursue claims for their loved one’s wrongful death. Compensation may include:

  • Pain, suffering, and mental anguish from the loss of a loved one
  • Loss of financial support of a loved one
  • Funeral expenses

Affected patients are encouraged to speak with a Glyxambi lawsuit attorney to learn more about their rights and remedies.

Contact Us For More Information

If you or a loved one took Glyxambi and suffered complications, contact Attorney Group for more information. You can fill out the form on this page, call us at the number listed at the top of the page, or email us at info@attorneygroup.com.

When you contact us, an attorney will follow up with you to speak with you about your case or answer questions that you might have. There is no cost or obligation to speak with us, and any information you provide will be kept confidential.

Please note that the law limits the time you have to pursue a claim for an injury. If you think you have a case, you should not delay taking action.

See our Frequently Asked Questions page for more information, and contact Attorney Group today.

Comments